Gujarat Terce Laboratories Ltd
NSE: BSE: 524314
₹38.36
(-3.28%)
Wed, 04 Mar 2026, 04:47 am
Market Cap298.87M
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KGujarat Terce Laboratories Analysis
dividend
- Unable to evaluate Gujarat Terce Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Gujarat Terce Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Gujarat Terce Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Gujarat Terce Laboratories is profitable, therefore cash runway is not a concern.
- Gujarat Terce Laboratories is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 5.5x debt.
- Gujarat Terce Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (32.5% vs 19.6% today).
- Interest payments on debt are well covered by earnings (EBIT is 49.7x coverage).
- Gujarat Terce Laboratories's level of debt (19.6%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- High level of physical assets or inventory.
management
- The tenure for the Gujarat Terce Laboratories board of directors is about average.
- Natwarbhai's remuneration is lower than average for companies of similar size in India.
- Natwarbhai's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Gujarat Terce Laboratories management team is less than 2 years, this suggests a new team.
misc
- Gujarat Terce Laboratories is not covered by any analysts.
- Gujarat Terce Laboratories has significant price volatility in the past 3 months.
past
- Gujarat Terce Laboratories's 1-year earnings growth exceeds its 5-year average (666.4% vs 44.5%)
- Gujarat Terce Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- Gujarat Terce Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Gujarat Terce Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (666.4% vs 22.7%).
- Gujarat Terce Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Gujarat Terce Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Gujarat Terce Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- Gujarat Terce Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Gujarat Terce Laboratories is good value based on earnings compared to the India market.
- 524314 outperformed the Market in India which returned -14.5% over the past year.
- 524314 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:524314 is down -12.9% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524314 is down -12.9% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800